On Demand

IBRANCE® (palbociclib) indication

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

Ibrance is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:1

• In combination with an aromatase inhibitor;
• In combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

References
1. IBRANCE Summary of Product Characteristics

On Demand

IBRANCE® (palbociclib) mode of action

Pfizer

IBRANCE works synergistically with ET to prevent cell proliferation2,3
IBRANCE acts downstream from ER2,3. It inhibits CDK 4/6 and helps to control cancer cell proliferation by inducing G1 arrest and reducing cell cycle progression2,3
IBRANCE in combination with ET results in increased and sustained cell cycle arrest compared with ET alone2,3

References:
1. IBRANCE Summary of Product Characteristics
2. Rocca A, et al. Expert Opin Pharmacother. 2014;15(3):407-20
3. Cadoo KA, et al. Breast Cancer: Targets and Therapy. 2014;6:123-33

On Demand

IBRANCE® (palbociclib) dosing

Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead

FBCs are the only monitoring requirement with IBRANCE.1* Prior to initiating treatment with IBRANCE, patients should have their full blood count, liver function tests and urea and electrolytes testing, as well as testing as clinically required throughout treatment.1

It is recommended to monitor FBCs on Days 1 and 15 of the first cycle and on Day 1 of each cycle thereafter.1

For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles, FBCs for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.

*Other tests as clinically required
1. IBRANCE Summary of Product Characteristics.

On Demand

Why vaccinate HIV positive adults?

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about the British HIV Association (BHIVA) vaccination recommendation for Prevenar 13 (PCV 13).

On Demand

British HIV Association (BHIVA) Access and Re-imbursement

Frances Chatham

Overview: This short video features lead practice nurse and trainer Frances Chatham talking about access and reimbursement for Prevenar 13 (PCV13) associated with the BHIVA vaccination recommendation for PCV13. 

Considerations when selecting a treatment for 2nd line mRCC patients
On Demand

Considerations when selecting a 2nd line treatment for mRCC patients

Various speakers

Pfizer logo for various speakers

In this video, leading mRCC experts provide their views on how to select a 2nd line treatment for their mRCC patients. This interview was recorded on 23 June 2017.

Treatment selection in 2nd line mRCC
On Demand

Treatment selection in 2nd line mRCC

Dr Enrique Grande

Dr Enrique Grande

In this interview, Dr Enrique Grande provides his approach to treatment selection in 2nd line mRCC. In particular, he describes how he would use Inlyta in favourable risk patients and patients who had a long-lasting clinical benefit to a TKI in the 1st line setting. This interview was recorded on the 23 June 2017.

Patients most likely to benefit from axitinib
On Demand

Which patients are most likely to benefit from axitinib?

Various speakers

Pfizer logo for various speakers

In this video, leading mRCC experts provide their views on which patients are most likely to benefit from Inlyta in 2nd line mRCC. This interview was recorded on the 23 June 2017.

On Demand

Prof Roy Fleischmann: ORAL Strategy trial

Prof Fleischmann

Professor Fleischmann's summary of the methodology of the ORAL Strategy trial and presentation of the results.

On Demand

Prof Rieke Alten: Unmet needs and patient reported outcomes

Prof Alten

Professor Alten discusses the state of unmet needs of rheumatoid arthitis sufferers, and the patient-reported outcomes from the tofacitinib phase III trials.